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Abstract
Glycogen hepatopathy (GH), a rare glycogen storage disease caused by genetic or acquired overactivation of
hepatic glycogen synthesis enzymes, can mimic non-alcoholic fatty liver disease (NAFLD). We describe a
case of biopsy-proven GH in an adult with type 1 diabetes mellitus (DM).
A 33-year-old Honduran woman with a 25-year history of type 1 DM complicated by gastroparesis, multiple
episodes of diabetic ketoacidosis (DKA) and hypoglycemia, and recurrent pancreatitis was referred for
abnormal liver enzymes. Family history was negative for liver disease. There was no history of alcohol or
recreational drug use. Patients' medications included insulin and thyroxine. Physical exam showed
hepatomegaly but no stigmata of chronic liver disease. Aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) had ranged from 100’s to over 7000 U/L while alkaline phosphatase (ALP) was
elevated to over 400 IU/L. Albumin, total bilirubin, platelets, international normalized ratio (INR),
eosinophils, viral hepatitis panel, antinuclear antibody (ANA), smooth muscle antibody (Ab), anti-liver-
kidney microsomal (LKM) Ab, celiac serologies, ceruloplasmin, alpha 1 antitrypsin, iron studies, and
acetaminophen levels were all normal. An abdominal ultrasound showed “fatty liver” and an atrophic
pancreas. CT abdomen showed hepatomegaly. The common bile duct (CBD) was found to be normal on
endoscopic ultrasound (EUS) and magnetic resonance cholangiopancreatography (MRCP). A liver biopsy was
pursued eventually, demonstrating glycogenotic hepatocytes.
GH is frequently misdiagnosed as NAFLD, a more common liver disease that occurs in association with
diabetes While GH is known to be reversible, NAFLD has been known to progress to advanced liver disease,
ranging from cirrhosis to hepatocellular carcinoma. Definite diagnosis often requires liver biopsy because of
overlapping clinical and radiographical pictures. Elevation of both glucose and insulin levels in the setting of
fragile DM control is thought to play a role via overstimulation of glycogen synthesis. Recommended
treatment is stable “tight” glycemic control; pancreatic transplantation has resulted in sustained GH
remission in two case reports. The required degree of stability and tightness of glucose control is not yet
known. An increased awareness of GH is needed in an attempt to prevent delay in diagnosis, in a condition
with an otherwise unknown incidence. 
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Introduction
Glycogen hepatopathy (GH) was first discovered in the 1930s in children with brittle diabetes, as part of a
condition known as Mauriac syndrome with these patients demonstrating growth retardation and
Cushingoid features [1]. It was then shown that GH can actually be present without Mauriac syndrome and
can be found in adult patients with poorly controlled type 1 diabetes. GH has since then been described as a
rare condition that often goes unrecognized, not often included in the differential diagnosis in patients with
elevated liver transaminases [2]. More importantly, it often gets confused with non-alcoholic fatty liver
disease (NAFLD), a more common liver abnormality associated with uncontrolled diabetes mellitus (DM) [3].
GH is due to glycogen accumulation in hepatocytes and presents with massive hepatomegaly and elevated
liver transaminases from acute parenchymal liver injury [1]. Other terms that have been used to describe
this condition are hepatic glycogenosis, liver glycogen storage, liver glycogenosis, and DM-associated
glycogen storage hepatomegaly [3]. We describe a case of GH that, similar to cases described in the current
literature, not only portrays the challenge faced by physicians when diagnosing this condition, but also the
importance of distinguishing this from NAFLD. Our aim, in this case, is to increase awareness of GH in an
attempt to prevent delay in diagnosis, in a condition with unknown incidence.
This case report was previously presented as an abstract at the ACG 2019 Annual Scientific Meeting
Abstracts; San Antonio, Texas [4].
Case Presentation
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Our patient is a 33-year-old Honduran female with poorly-controlled diabetes (hemoglobin A1c of 9.5% to
11%), diagnosed at the age of 8, requiring multiple hospitalizations secondary to diabetic ketoacidosis (DKA)
with findings of elevated aminotransferases [4]. Her medical history is notable for severe gastroparesis,
requiring endoscopic botox injections, recurrent pancreatitis of unknown etiology, and hypothyroidism. Her
surgical history was significant for cholecystectomy done in her mid-20s. In terms of her social history, she
had denied any alcohol use, smoking, or usage of any recreational drugs. There was no known family history
of any gastrointestinal pathology.
At the age of 25, the patient had initially presented with dyspepsia, early satiety, and diarrhea that required
her to obtain an endoscopy demonstrating gastritis but with no other abnormal findings otherwise. During
that time, she required a five-day hospital stay due to noted abnormal liver tests that were attributed to
gastroenteritis at that time, as the patient had no history of alcohol abuse, no evidence of cholelithiasis, and
a negative hepatitis panel. During her mid-20s, the patient was found to have numerous hospital admission
secondary to DKA, at which time the patient was found to have erratic blood sugars (40s-500s) with an
endocrinologist closely following her case. Her diabetes was being treated with both Tresiba (insulin
degludec) and inhaled insulin, Afrezza. It was at this time that she was also found to have significant
elevations in her liver tests, which consisted (at their highest) of an aspartate aminotransferase (AST) of
7,184 U/L (reference: 8-48 U/L), alanine aminotransferase (ALT) of 650 U/L (reference: 7-55 U/L), and
alkaline phosphatase (ALP) of 443 U/L (reference: 40-129 U/L). Physical exam demonstrated hepatomegaly,
which was confirmed on CT. She continued to present to the hospital numerous times with these flares,
found to have fluctuations in both her blood glucose levels and aminotransferases. Other imaging, such as an
abdominal ultrasound during these times had demonstrated fatty liver with an atrophic pancreas. She also
had had multiple endoscopic ultrasounds and magnetic resonance cholangiopancreatography (MRCP) that
demonstrated normal common bile duct (CBD). Due to this, the patient was tested for numerous other
etiologies for the cause of these findings, including autoimmune hepatitis, infectious, ischemic, and drug-
induced hepatitis, all being ruled out at this time. Some of these tests included a hepatitis panel,
acetaminophen levels, ceruloplasmin level, alpha-1-anitrypsin level, anti-tissue transglutaminase antibody
just to name a few.
Finally, after exhausting some of these diagnostic tests, our patient was sent for a liver biopsy for further
evaluation and to definitively rule out an autoimmune cause for her condition. The liver biopsy, however,
demonstrated glycogenotic hepatocytes with the patient subsequently being diagnosed with GH. Subsequent
hospitalizations were due to abdominal pain, nausea, and vomiting secondary to gastroparesis and chronic
pancreatitis. She continued to frequently obtain endoscopic Botox injections for her gastroparesis, as well as
celiac plexus block for the alleviation of her pain due to pancreatitis. Her blood glucose levels remained
better controlled during these later hospitalizations, with less frequent hypoglycemic episodes, which was
reflected on her liver tests that appeared mildly elevated to almost normal. This improvement was
additionally portrayed on repeat imaging done during one of the patient's later hospitalizations (Figures
1-2).
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FIGURE 1: MRI of the abdomen demonstrating markedly enlarged liver
during one of the patient's hospitalizations
FIGURE 2: MRI of the abdomen during one of the patient's
hospitalizations with improved hepatomegaly, demonstrating the
reversibility of this condition
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Discussion
GH is a condition that has been associated with uncontrolled type 1 DM, particularly in those with
fluctuations in both blood glucose and insulin levels. It has rarely been seen in uncontrolled type 2 diabetics,
and even less frequently has been associated with conditions such as dumping syndrome after gastrectomy,
anorexia nervosa, use of high-dose steroids, azathioprine, and insulin overdose [5]. None of which were
present in our patient. It is a condition with no known gender predominance and is seen in both children
and adults [6].
The pathophysiology of GH is due to the transport of glucose into hepatocytes due to its conversion to
glucose-6-phosphate via glucokinase and then subsequently being converted to glycogen via glycogen
synthase [6]. Glycogen synthase is activated after dephosphorylation by phosphatase, an enzyme whose
concentration and activity is dependent on insulin and the presence of glucose [6]. This is the main
determinant for why both an elevation of blood glucose and insulin levels are needed for the development of
GH [6]. Known exacerbating factors are frequent hypoglycemic episodes, as witnessed in our patient, that are
commonly seen in type 1 diabetic patients. In fact, hypoglycemia from poor diabetes control, along with
aggressive insulin therapy, is what drives the development of this condition, as seen in our patient [3]. Its
rarity might be due to defects in genes coding for regulatory proteins, such as laforin, which in turn
regulates the activity of glycogen synthase and/or glucose-6-phosphatase [2]. Another study demonstrated
that a structural defect on the glycogen phosphorylase gene (PYGL) may be involved in glycogen
accumulation [6].
Clinically, patients with GH can present with many nonspecific signs and symptoms, such as abdominal
pain, nausea, and vomiting, the most common being hepatomegaly with lab work indicative of elevated
transaminases. While lab results typically demonstrate elevated liver enzymes with a predominantly
hepatocellular pattern, they may also have elevated alkaline phosphatase or bilirubin levels indicating
cholestatic injury (albeit a much smaller component) as was the case in our patient [6]. Another important
finding that may help distinguish this condition from others is the AST dominant elevation, most often seen
in these patients, that was most definitely seen in our patient [7]. In a patient presenting like ours, many
different diagnoses come to mind, with ischemic, infectious, and autoimmune causes being the top of the
differentials. In our case, these causes were ruled out immediately with the laboratory tests that had been
ordered.
Based on the above findings, it is easy to see why this condition is most frequently misdiagnosed with
NAFLD, another condition associated with diabetes, but with a very different prognosis. While GH has been
shown to be reversible, NAFLD has been known to progress to advanced liver disease, ranging from cirrhosis
to hepatocellular carcinoma [7]. The challenge is distinguishing GH from NAFLD as both appear the same,
clinically and radiographically, with a definitive diagnosis made with liver biopsy. Histologically, in GH, you
will discover marked glycogen accumulation leading to pale, swollen hepatocytes on hematoxylin and eosin
stain with an otherwise intact architecture and no significant fibrosis [6]. Staining with periodic acid-Schiff
(PAS) demonstrates a significant amount of cytoplasmic glycogen deposits, disappearing after digestion
with diastase [6]. Many other conditions may be associated with these findings, including glycogen storage
disease, high-dose steroids, and medications (phenytoin); findings that can be easily excluded with a
thorough history from our patients [6]. However, while abdominal ultrasound may not be helpful in
distinguishing these two conditions, a CT abdomen may be able to provide some clues with the liver
appearing more dense and, therefore, bright in patients with GH vs those with NAFLD [6]. Another
diagnostic modality that has been described in the literature is a gradient dual-echo MRI, that may
distinguish glycogen from fat and further assist in differentiating it from NAFLD, with the sole purpose of
using these less invasive options as clues in diagnosing this condition earlier in the course [8].
While the exact mechanism of this condition is still being studied, the one thing we do know is that
treatment consists of tighter glycemic control, with noticeable changes noted within 2 to 14 weeks [7].
Although, in our patient, and many other published cases, the glycemic control may not always correlate
directly with elevation of liver tests. In fact, like our patient whose transaminases improved despite
improvements in glycohemoglobin levels, there is still much to be known about the degree of improved
glycemic control needed for the resolution of GH [9]. In one study, two patients treated with pancreas
transplantation were noted to have a complete reversal of their GH, inducing an insulin-independent,
euglycemic state [10]. This procedure was performed in those with severe secondary complications of
diabetes, including kidney failure [10]. Although our patient did not have kidney failure, she did have severe
gastroparesis requiring frequent endoscopic Botox injections could possibly be a candidate for pancreatic
transplantation.
Conclusions
Based on our case and review of the current literature, there is still much to be known about GH. While this
condition has been around since the 1930s, there is still a paucity of knowledge regarding the biochemical
defects, prevalence, characteristics, and risk factors involved. While we know this condition relies upon
elevation of both glucose and insulin levels, the improvement in glycemic levels needed prior to the
resolution of GH is still something that remains undetermined. We hope that by presenting this case, it
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allows physicians to be aware of a disease that is often confused with a more well-known condition that
presents almost identically, known as NAFLD. This will hopefully lead us to further investigate the role of
both the aforementioned and hopefully newer diagnostic modalities in distinguishing GH and whether this
can help prevent a delay in diagnosis. More than anything, this case demonstrates the importance of
keeping GH in the differential when you are investigating the cause of elevated liver enzymes, particularly
in an uncontrolled type 1 diabetic.
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